{"presentation":{"slides":[{"elements":[{"x":14.161220043572985,"y":10.799136069114471,"width":73.63834422657952,"height":75.5939524838013,"action":{"library":"H5P.Table 1.1","params":{"text":"\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of TB<\/span><\/span><\/span>\n\n\t\t\tnotified patients<\/span><\/span><\/span>\n\n\t\t\twith UDST tested<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of TB notified of patients with<\/span><\/span><\/span>\n\n\t\t\tUDST tested.<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tTotal TB notified patients<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"219f2587-5dbf-46da-bb22-0e75d00dda90","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":8.714596949891067,"y":43.2842332613391,"width":81.69934640522877,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 1,000 TB notified patients during a year, and 800 of them underwent UDST testing, the proportion of TB notified patients with UDST tested would be:<\/p>\n\n

(800\/1,000) x 100 = 80%<\/p>\n\n

So in this example, 80% of all notified TB patients underwent UDST testing.<\/p>\n"},"subContentId":"7dbbdb0c-cb42-4425-96d7-ff3d0ffa3acf","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":15.250544662309368,"y":15.11879049676026,"width":79.520697167756,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of MDR TB cases initiated on treatment among diagnosed<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of RR\/ MDR TB notified patients initiated on DRTB regimen<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tTotal RR\/ MDR TB noti\uf001ed patients<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"e14b11c8-aead-4651-b5e7-a13662944ee0","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":14.161220043572984,"y":56.32764578833693,"width":76.25272331154684,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 500 RR\/MDR TB notified patients during a year, and 400 of them were initiated on a DRTB treatment regimen, the proportion of MDR TB cases initiated on treatment among diagnosed would be:<\/p>\n\n

(400\/500) x 100 = 80%<\/p>\n\n

So in this example, 80% of all RR\/MDR TB notified patients were initiated on a DRTB treatment regimen.<\/p>\n"},"subContentId":"785d35f4-79b7-4977-9738-e64ab83789b9","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":13.071895424836601,"y":10.799136069114471,"width":75.16339869281046,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of Rif resistance patients subjected to baseline SL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of Rif resistance patients (RR\/MDR TB) subjected to baseline SL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tTotal number of Rif resistance patients (RR\/MDR TB) diagnosed<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"25eeb58d-45bf-43d2-ac82-44ce11c05ab5","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":11.982570806100219,"y":49.827861771058316,"width":72.98474945533769,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 300 Rif resistance patients (RR\/MDR TB) diagnosed during a year, and 240 of them underwent baseline SL-LPA testing, the proportion of Rif resistance patients subjected to baseline SL-LPA would be:<\/p>\n\n

(240\/300) x 100 = 80%<\/p>\n\n

So in this example, 80% of all Rif resistance patients (RR\/MDR TB) diagnosed underwent baseline SL-LPA testing.<\/p>\n"},"subContentId":"5f54537e-a891-4c6c-a6f6-44b84e3bffd7","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":11.982570806100219,"y":12.958963282937365,"width":80.61002178649238,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of patients with results available among subjected to Base line SL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of RR\/ MDR TB patients with baseline SL-LPA results reported<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of RR\/ MDR TB patients subjected to base line SL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"23a95af1-ed3f-435f-9058-2242dc39e772","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":11.982570806100219,"y":51.997840172786184,"width":74.07407407407408,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

during a year, and results were reported for 180 of them, the proportion of patients with results available among those subjected to baseline SL-LPA would be:<\/p>\n\n

(180\/200) x 100 = 90%<\/p>\n\n

So in this example, 90% of all RR\/MDR TB patients who underwent baseline SL-LPA testing had their results reported.<\/p>\n"},"subContentId":"6c171c12-4dab-4c25-b8f7-1a7edce6c3be","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":14.161220043572985,"y":12.958963282937365,"width":76.25272331154684,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of RR\/MDR TB patients with additional resistance to SLI or FQ or both SLI & FQ diagnosed among RR\/ MDR TB patients with BL-SL LPA results reported<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of RR\/ MDR TB patients with additional resistance diagnosed<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of RR\/ MDR TB patients with base line SL-LPA results reported<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"0d5e413b-2b31-4007-8d3a-3120e3966775","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":6.5359477124183005,"y":56.15550755939525,"width":89.32461873638344,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 150 RR\/MDR TB patients with baseline SL-LPA results reported during a year, and 30 of them were diagnosed with additional resistance to SLI or FQ or both SLI & FQ, the proportion of RR\/MDR TB patients with additional resistance would be:<\/p>\n\n

(30\/150) x 100 = 20%<\/p>\n\n

So in this example, 20% of all RR\/MDR TB patients with baseline SL-LPA results reported were diagnosed with additional resistance to SLI or FQ or both SLI & FQ.<\/p>\n"},"subContentId":"9cccce04-ea8b-43b1-8b28-62715adf4650","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":15.250544662309368,"y":15.11879049676026,"width":68.62745098039215,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of Rifampicin sensitive TB patients subjected to FL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of Rif sensitive patients subjected to baseline FL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tTotal number of Rif sensitive patients diagnosed<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"ee85189c-2960-485c-a080-53aaac58a7a9","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":8.714596949891067,"y":51.997840172786184,"width":80.61002178649238,"height":39.956803455723545,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 500 Rifampicin-sensitive TB patients diagnosed during a year, and 200 of them underwent baseline FL-LPA testing, the proportion of Rifampicin-sensitive TB patients subjected to FL-LPA would be:<\/p>\n\n

(200\/500) x 100 = 40%<\/p>\n\n

So in this example, 40% of all Rifampicin-sensitive TB patients diagnosed during the year underwent baseline FL-LPA testing.<\/p>\n"},"subContentId":"882e3318-735e-40fb-9173-06a63d25bf2a","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":13.071895424836601,"y":8.639308855291576,"width":77.34204793028323,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tProportion of Rifampicin sensitive patients with H-mono \/ poly resistance report available among tested for FL-LPs<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of Rifampicin sensitive patients with H-mono \/ poly resistance reports available<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t

\n\t\t\tNumber of Rifampicin sensitive patients subjected to FL-LPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t

\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t

\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"5c258caa-ba93-4976-8c3e-a4aa17442a7d","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":4.357298474945534,"y":49.827861771058316,"width":92.5925925925926,"height":45.35637149028078,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

For example, if there were 200 Rifampicin-sensitive TB patients who underwent FL-LPA testing during a year, and 50 of them were diagnosed with H-mono\/poly resistance and had the resistance report available, the proportion of Rifampicin-sensitive patients with H-mono\/poly resistance report available among those tested for FL-LPA would be:<\/p>\n\n

(50\/200) x 100 = 25%<\/p>\n\n

So in this example, 25% of all Rifampicin-sensitive TB patients who underwent FL-LPA testing during the year and were diagnosed with H-mono\/poly resistance had the resistance report available.<\/p>\n"},"subContentId":"89693b02-947b-4d22-87cf-c578881cac89","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":11.982570806100219,"y":6.479481641468682,"width":79.520697167756,"height":39.956803455723545,"action":{"library":"H5P.Table 1.1","params":{"text":"

\n\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\t

\n\t\t\tIndicator <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t	\n\t\t\tFormula <\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t	\n\t\t\t \n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t
\n\t\t\tProportion of H-mono \/ poly resistance TB cases diagnosed amongst those subjected to FLLPA<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t	\n\t\t\tNumerator:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t	\n\t\t\tNumber of Rifampicin sensitive patients with H-mono \/ poly resistance diagnosed<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t
\n\t\t\tDenominator:<\/span><\/span><\/span>\n\n\t\t\t \n\t\t\t<\/td>\n\t\t\t	\n\t\t\tNumber of Rifampicin sensitive patients subjected to FL-LPA with reports available<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t
\n\t\t\tMultiplier:<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t\t	\n\t\t\t100<\/span><\/span><\/span>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n"},"subContentId":"931656b4-a3f0-4368-a107-1e06cb386f3f","metadata":{"contentType":"Table","license":"U","title":"Untitled Table"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":5.446623093681917,"y":49.72656587473002,"width":90.41394335511983,"height":44.27645788336933,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":" For example, if there were 200 Rifampicin-sensitive TB patients who underwent FL-LPA testing during a year, and 100 of them had the resistance report available, out of which 20 were diagnosed with H-mono\/poly resistance, the proportion of H-mono\/poly resistance TB cases diagnosed among those subjected to FLLPA would be:<\/p>\n\n (20\/100) x 100 = 20%<\/p>\n\n So in this example, 20% of all Rifampicin-sensitive TB patients who underwent FL-LPA testing during the year and had the resistance report available were diagnosed with H-mono\/poly resistance.<\/p>\n"},"subContentId":"963ac685-fb4f-4f92-b000-5ac576f7fe07","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}}],"keywordListEnabled":true,"globalBackgroundSelector":{},"keywordListAlwaysShow":false,"keywordListAutoHide":false,"keywordListOpacity":90},"override":{"activeSurface":false,"hideSummarySlide":false,"summarySlideSolutionButton":true,"summarySlideRetryButton":true,"enablePrintButton":false,"social":{"showFacebookShare":false,"facebookShare":{"url":"@currentpageurl","quote":"I scored @score out of @maxScore on a task at @currentpageurl."},"showTwitterShare":false,"twitterShare":{"statement":"I scored @score out of @maxScore on a task at @currentpageurl.","url":"@currentpageurl","hashtags":"h5p, course"},"showGoogleShare":false,"googleShareUrl":"@currentpageurl"}},"l10n":{"slide":"Slide","score":"Score","yourScore":"Your Score","maxScore":"Max Score","total":"Total","totalScore":"Total Score","showSolutions":"Show solutions","retry":"Retry","exportAnswers":"Export text","hideKeywords":"Hide sidebar navigation menu","showKeywords":"Show sidebar navigation menu","fullscreen":"Fullscreen","exitFullscreen":"Exit fullscreen","prevSlide":"Previous slide","nextSlide":"Next slide","currentSlide":"Current slide","lastSlide":"Last slide","solutionModeTitle":"Exit solution mode","solutionModeText":"Solution Mode","summaryMultipleTaskText":"Multiple tasks","scoreMessage":"You achieved:","shareFacebook":"Share on Facebook","shareTwitter":"Share on Twitter","shareGoogle":"Share on Google+","summary":"Summary","solutionsButtonTitle":"Show comments","printTitle":"Print","printIngress":"How would you like to print this presentation?","printAllSlides":"Print all slides","printCurrentSlide":"Print current slide","noTitle":"No title","accessibilitySlideNavigationExplanation":"Use left and right arrow to change slide in that direction whenever canvas is selected.","accessibilityCanvasLabel":"Presentation canvas. Use left and right arrow to move between slides.","accessibilityProgressBarLabel":"Choose slide to display","containsNotCompleted":"@slideName contains not completed interaction","containsCompleted":"@slideName contains completed interaction","slideCount":"Slide @index of @total","containsOnlyCorrect":"@slideName only has correct answers","containsIncorrectAnswers":"@slideName has incorrect answers","shareResult":"Share Result","accessibilityTotalScore":"You got @score of @maxScore points in total","accessibilityEnteredFullscreen":"Entered fullscreen","accessibilityExitedFullscreen":"Exited fullscreen","confirmDialogHeader":"Submit your answers","confirmDialogText":"This will submit your results, do you want to continue?","confirmDialogConfirmText":"Submit and see results","slideshowNavigationLabel":"Slideshow navigation"}}

Search

Monitoring indicators related to UDST

Content Status

Type

Linked Node

Monitoring indicators related to UDST

Content Creator

Reviewer

Target Audience